|
rs1047303
|
|
|
0.010 |
GeneticVariation |
BEFREE |
A common 1245 A→C missense-encoding single nucleotide polymorphism in HSD3B1 (rs1047303), the gene that encodes this enzyme, leads to a more stable protein that is resistant to degradation and thus increased production of potent androgens from adrenal precursors, facilitating castration-resistant PCa development.
|
31271415 |
2019 |
|
rs2149556
|
|
|
0.010 |
GeneticVariation |
BEFREE |
A multivariate model consisting of age, GS, rs2149556 (HR 0.67; 95% CI 0.38-1.18) and rs4372063 (HR 2.17; 95% CI 1.25-3.76) was constructed to predict survival in patients with CRPC (concordance of 0.69, P < 3.2 × 10<sup>-9</sup> ).
|
27410686 |
2017 |
|
rs4372063
|
|
|
0.010 |
GeneticVariation |
BEFREE |
A multivariate model consisting of age, GS, rs2149556 (HR 0.67; 95% CI 0.38-1.18) and rs4372063 (HR 2.17; 95% CI 1.25-3.76) was constructed to predict survival in patients with CRPC (concordance of 0.69, P < 3.2 × 10<sup>-9</sup> ).
|
27410686 |
2017 |
|
rs564250
|
|
|
0.010 |
GeneticVariation |
BEFREE |
In metastatic prostate cancer, the AG/GG allele in GSTM3 rs7483 and CT/TT allele in CAT rs564250 were associated with a significantly lower risk of progression to CRPC and all-cause death compared with homozygotes of the major AA allele (hazard ratio [HR]; [95% confidence interval (CI)], 0.55 [0.34-0.86], P = 0.0086) and CC allele (HR; [95% CI], 0.48 [0.24-0.88], P = 0.016), respectively.
|
27993795 |
2017 |
|
rs7483
|
|
|
0.010 |
GeneticVariation |
BEFREE |
In metastatic prostate cancer, the AG/GG allele in GSTM3 rs7483</span> and CT/TT allele in CAT rs564250 were associated with a significantly lower risk of progression to CRPC and all-cause death compared with homozygotes of the major AA allele (hazard ratio [HR]; [95% confidence interval (CI)], 0.55 [0.34-0.86], P = 0.0086) and CC allele (HR; [95% CI], 0.48 [0.24-0.88], P = 0.016), respectively.
|
27993795 |
2017 |
|
rs1395
|
|
|
0.010 |
GeneticVariation |
BEFREE |
No relation to risk was found.Three SNPs were associated with CRPC prognosis in Caucasians: ABCB11 rs7602171G>A (p = 0.003; n = 30; hazard ratio [HR]: 0.307), GSTP1 rs1799811C>T (p = 0.001; n = 38; HR: 0.254) and SLC5A6 rs1395 (p = 0.004; n = 35; HR: 3.15).
|
27883295 |
2016 |
|
rs1799811
|
|
|
0.010 |
GeneticVariation |
BEFREE |
No relation to risk was found.Three SNPs were associated with CRPC prognosis in Caucasians: ABCB11 rs7602171G>A (p = 0.003; n = 30; hazard ratio [HR]: 0.307), GSTP1 rs1799811C>T (p = 0.001; n = 38; HR: 0.254) and SLC5A6 rs1395 (p = 0.004; n = 35; HR: 3.15).
|
27883295 |
2016 |
|
rs7602171
|
|
|
0.010 |
GeneticVariation |
BEFREE |
No relation to risk was found.Three SNPs were associated with CRPC prognosis in Caucasians: ABCB11 rs7602171G>A (p = 0.003; n = 30; hazard ratio [HR]: 0.307), GSTP1 rs1799811C>T (p = 0.001; n = 38; HR: 0.254) and SLC5A6 rs1395 (p = 0.004; n = 35; HR: 3.15).
|
27883295 |
2016 |
|
rs2208532
|
|
|
0.010 |
GeneticVariation |
BEFREE |
We studied the polymorphisms rs518673 and rs166050 in SRD5A1, and rs12470143, rs523349, rs676033 and rs2208532 in SRD5A2 as well as the time to CRPC progression and overall survival in 104 patients with metastatic prostate cancer that had undergone primary ADT.
|
26169017 |
2015 |
|
rs5472
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Haptoglobin promoter polymorphism rs5472 as a prognostic biomarker for peptide vaccine efficacy in castration-resistant prostate cancer patients.
|
26428930 |
2015 |
|
rs676033
|
|
|
0.010 |
GeneticVariation |
BEFREE |
We studied the polymorphisms rs518673 and rs166050 in SRD5A1, and rs12470143, rs523349, rs676033 and rs2208532 in SRD5A2 as well as the time to CRPC progression and overall survival in 104 patients with metastatic prostate cancer that had undergone primary ADT.
|
26169017 |
2015 |
|
rs1004467
|
|
|
0.010 |
GeneticVariation |
BEFREE |
In the logistic regression analysis four genetic polymorphisms, rs743572, rs6162, rs6163, and rs1004467, in the CYP17A1 gene were significantly associated with a risk of progression to CRPC (p < 0.05).
|
22714708 |
2013 |
|
rs12422149
|
|
|
0.010 |
GeneticVariation |
BEFREE |
We studied the progression to CRPC for the SLCO1B3 rs4149117 and SLCO2B1 rs12422149 genotypes in 87 prostate cancer patients who received androgen deprivation therapy (ADT).
|
23896625 |
2013 |
|
rs4149117
|
|
|
0.010 |
GeneticVariation |
BEFREE |
We studied the progression to CRPC for the SLCO1B3 rs4149117 and SLCO2B1 rs12422149 genotypes in 87 prostate cancer patients who received androgen deprivation therapy (ADT).
|
23896625 |
2013 |
|
rs6162
|
|
|
0.010 |
GeneticVariation |
BEFREE |
In the logistic regression analysis four genetic polymorphisms, rs743572, rs6162, rs6163, and rs1004467, in the CYP17A1 gene were significantly associated with a risk of progression to CRPC (p < 0.05).
|
22714708 |
2013 |
|
rs6163
|
|
|
0.010 |
GeneticVariation |
BEFREE |
In the logistic regression analysis four genetic polymorphisms, rs743572, rs6162, rs6163, and rs1004467, in the CYP17A1 gene were significantly associated with a risk of progression to CRPC (p < 0.05).
|
22714708 |
2013 |
|
rs743572
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Cox regression analysis for these SNPs showed an association of risk of progression to CRPC with the rs743572 genotype (p = 0.02, odds ratio [OR] 0.43, 95 % confidence interval [CI] 0.22-0.85).
|
22714708 |
2013 |
|
rs1045642
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Serum LDH may be a promising predictor of prognosis, and the ABCB1 C3435T polymorphism may be a genetic predictor of the severity of leukocytopenia in patients with CRPC treated with DEC.
|
21706123 |
2012 |
|
rs2234693
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Patients with CRPC (n=115) treated with docetaxel, single-agent thalidomide (n=42), or healthy controls (n=289) were genotyped for the CYP19 R264C (rs700519) and the ERα PvuII T>C (rs2234693) and XbaI A>G (rs9340799) polymorphisms.
|
21106711 |
2011 |
|
rs700519
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Patients with CRPC (n=115) treated with docetaxel, single-agent thalidomide (n=42), or healthy controls (n=289) were genotyped for the CYP19 R264C (rs700519) and the ERα PvuII T>C (rs2234693) and XbaI A>G (rs9340799) polymorphisms.
|
21106711 |
2011 |
|
rs747099645
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Patients with CRPC (n=115) treated with docetaxel, single-agent thalidomide (n=42), or healthy controls (n=289) were genotyped for the CYP19 R264C (rs700519) and the ERα PvuII T>C (rs2234693) and XbaI A>G (rs9340799) polymorphisms.
|
21106711 |
2011 |
|
rs9340799
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Patients with CRPC (n=115) treated with docetaxel, single-agent thalidomide (n=42), or healthy controls (n=289) were genotyped for the CYP19 R264C (rs700519) and the ERα PvuII T>C (rs2234693) and XbaI A>G (rs9340799) polymorphisms.
|
21106711 |
2011 |
|
rs77375493
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Activating mutation (V617F) in the tyrosine kinase JAK2 is absent in locally-confined or castration-resistant prostate cancer.
|
20966544 |
2010 |
|
rs775174909
|
|
|
0.010 |
GeneticVariation |
BEFREE |
513 patients with castrate-resistant prostate cancer (CRPC), including 284 patients who received radiotherapy, 229 patients without radiotherapy and 152 healthy individuals were genotyped for five polymorphisms in DNA excision repair genes:ERCC1 N118N (500C>T), XPD K751Q (2282A>C), XRCC1 R194W (685C>T), XRCC1 R399Q (1301G>A) and PARP1 V762A(2446T>C).
|
20495366 |
2010 |
|
rs886054499
|
|
|
0.010 |
GeneticVariation |
BEFREE |
513 patients with castrate-resistant prostate cancer (CRPC), including 284 patients who received radiotherapy, 229 patients without radiotherapy and 152 healthy individuals were genotyped for five polymorphisms in DNA excision repair genes:ERCC1 N118N (500C>T), XPD K751Q (2282A>C), XRCC1 R194W (685C>T), XRCC1 R399Q (1301G>A) and PARP1 V762A(2446T>C).
|
20495366 |
2010 |